OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Multi-Omics Data Integration Special Issue Features Research from CPTAC Investigators

The Journal of Molecular & Cellular Proteomics has released a special issue this month (August 2019) on Multi-Omics Integration.  The issue sets out to show how multi-omics research is integral to the understanding of biological...


More Validated Targeted MS-based Assays Released on the NCI Proteomics Assay Portal!

New assays have been released today!  CPTAC and researchers from the University of Victoria – Genome British Columbia Proteomics Centre just released over 130 quantitative, fit-for-purpose, multiplexed mouse multiple reaction monitoring (MRM) mass spectrometry (MS)-based  plasma assays for...


CPTAC Researchers Develop New Technique for Mapping the O-Glycoproteome

CPTAC researchers at John Hopkins University School of Medicine have developed a technique to reliably identify o-linked glycosylation sites and site-specific glycans with core...


Low Cell Input? No Problem! CPTAC Researchers Develop Low Sample Input Proteomics Protocol

Proteomic profiling often entails using a large sample input to explore the dynamic nature of protein expression and regulation. However, there are instances when researchers have the opposite due to prior methodology such as fluorescence activated cell sorting (FACS) or when dealing with...


Amsterdam UMC Joins the ICPC

June 13th, 2019 marked the addition of our 33rd institution to the International Cancer Proteogenomic Consortium (ICPC).  We are pleased to include Amsterdam UMC...


Proteomic Dataset Release of the CPTAC and CBTTC Collaborative Pediatric Brain Tumor Pilot Study

While it’s a common misconception that all tumors in the brain are the same, there are more than 120 subtypes of brain cancers with very diverse features and diagnosis.


Dr. Rodriguez Speaks at JSN, Fujita, and Nagoya University about the Power of Proteogenomics

Dr. Henry Rodriguez gave the keynote address at the 62nd Annual Meeting of the Japanese Society of Nephrology in Nagoya, Japan this week.  In line with the conference’s theme Open The Future, Dr.


The Magic of Proteogenomics Explained Series: CPTAC Proteogenomics Program

Since its first mention in the scientific literature in 2004 by Jaffe et al1, the term proteogenomics has been shrouded in mystery and thick technical language.  It is a complex idea, but one that is gaining traction as its value to improve our understanding of cancer development and potentially...


CPTAC Develops a New Technique (BASIL) to Enhance Phospho Sensitivity from a Small Population of Cells (feasibility on human pancreatic islets)

Phosphorylation is a key process in the regulation of protein activity and has long been appreciated as an essential mechanism for the control of cellular function - tells a protein where to go, what to bind to and even when to die.


Pages